American Journal of Kidney Diseases
Volume 45, Issue 3 , Pages 473-484 , March 2005

First United Kingdom Heart and Renal Protection (UK-HARP-I) study: Biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease

  • Colin Baigent, BMBCh

      Affiliations

    • Clinical Trial Service Unit, Oxford University, Oxford, UK
    • Corresponding Author InformationAddress reprint requests to Colin Baigent, BMBCh, Clinical Trial Service Unit, Radcliffe Infirmary, Oxford OX2 6HE, UK.
    • ,
  • Martin Landray, MD, PhD

      Affiliations

    • Clinical Trial Service Unit, Oxford University, Oxford, UK
    • ,
  • Craig Leaper, PhD

      Affiliations

    • Clinical Trial Service Unit, Oxford University, Oxford, UK
    • ,
  • Paul Altmann, MD (FRCP)

      Affiliations

    • Churchill Hospital, Oxford, UK
    • ,
  • Jane Armitage, MBBS, MFPH

      Affiliations

    • Clinical Trial Service Unit, Oxford University, Oxford, UK
    • ,
  • Alex Baxter, MA

      Affiliations

    • Clinical Trial Service Unit, Oxford University, Oxford, UK
    • ,
  • Hugh S. Cairns, MD

      Affiliations

    • Kings College Hospital, London, UK
    • ,
  • Rory Collins (FMedSci)

      Affiliations

    • Clinical Trial Service Unit, Oxford University, Oxford, UK
    • ,
  • Robert N. Foley, MB, MSc

      Affiliations

    • Hope Hospital, Salford, UK
    • ,
  • Valeria Frighi, MD

      Affiliations

    • Clinical Trial Service Unit, Oxford University, Oxford, UK
    • ,
  • Karen Kourellias

      Affiliations

    • Clinical Trial Service Unit, Oxford University, Oxford, UK
    • ,
  • Peter J. Ratcliffe (FRS)

      Affiliations

    • Churchill Hospital, Oxford, UK
    • ,
  • Mary Rogerson, MD (FRCP)

      Affiliations

    • Southampton General Hospital, Southampton, UK
    • ,
  • John E. Scoble, MD (FRCP)

      Affiliations

    • Guy’s Hospital, London, UK
    • ,
  • Charles R.V. Tomson, DM

      Affiliations

    • Southmead Hospital, Bristol, UK.
    • ,
  • David C. Wheeler, MD (FRCP)

      Affiliations

    • Royal Free Hospital, London, UK

Received 29 July 2004 ,Accepted 9 November 2004.

References 

  1. Scandinavian Simvastatin Survival Study Group . Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease (The Scandinavian Simvastatin Survival Study (4S)) . Lancet . 1994;344:1383–1389
  2. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group . Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels . N Engl J Med . 1998;339:1349–1357
  3. Cholesterol and Recurrent Events Trial Investigators Sacks FM , Pfeffer MA , Moyé LA , et al.   The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels . N Engl J Med . 1996;335:1001–1009
  4. Heart Protection Study Collaborative Group . MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals (A randomised placebo-controlled trial) . Lancet . 2002;360:7–22
  5. Heart Protection Study Collaborative Group . Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high-risk conditions . Lancet . 2004;363:757–767
  6. White HD , Simes RJ , Anderson NE , et al.   Pravastatin therapy and the risk of stroke . N Engl J Med . 2000;343:317–326
  7. Levey AS , Beto JA , Coronardo BE , et al.   Controlling the epidemic of cardiovascular disease in chronic renal failure (What do we know? What do we need to learn? Where do we go from here?) . Am J Kidney Dis . 1998;32:853–906
  8. National Kidney Foundation . K/DOQI Clinical Practice Guidelines for Managing Dyslipidemias in Chronic Kidney Disease . Am J Kidney Dis . 2003;41(suppl 3):S1–S91
  9. Degoulet P , Legrain M , Réach I , et al.   Mortality risk factors in patients treated by chronic haemodialysis . Nephron . 1982;31:103–110
  10. Lowrie EG , Lew NL . Death risk in hemodialysis patients (The predictive value of commonly measured variables and an evaluation of death rate differences between facilities) . Am J Kidney Dis . 1990;15:458–482
  11. US Renal Data System . USRDS 2000 Annual Report . Bethesda, MD: The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2000;
  12. Baigent C , Burbury K , Wheeler D . Premature cardiovascular disease in chronic renal failure . Lancet . 2000;356:147–152
  13. Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators Holdaas H , Fellstrom B , Jardine AG , et al.   Effect of fluvastatin on cardiac outcomes in renal transplant recipients (A multicentre, randomised, placebo-controlled trial) . Lancet . 2003;361:2024–2031
  14. Antithrombotic Trialists’ Collaboration . Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients . BMJ . 2002;324:71–86
  15. Jubelirer SJ . Hemostatic abnormalities in renal disease . Am J Kidney Dis . 1985;5:219–225
  16. Carvalho AC . Acquired platelet dysfunction in platelets with uremia . Hematol Oncol Clin North Am . 1990;4:129–143
  17. White SJ , Freedman LS . Allocation of patients to treatment groups in a controlled clinical study . Br J Cancer . 1978;37:849–857
  18. McNamara JR , Cole TG , Contois JH , Ferguson CA , Ordovas JM , Schaefer EJ . Immunoseparation method for measuring low-density lipoprotein cholesterol directly from serum evaluated . Clin Chem . 1995;41:232–240
  19. Jialal I , Hirany SV , Deveraj S , Sherwood TA . Comparison of an immunoprecipitation method for direct measurement of LDL cholesterol with beta-quantification (ultracentrifugation) . Am J Clin Pathol . 1995;104:76–81
  20. Oxford Cholesterol Study Group Keech A , Collins R , MacMahon S , et al.   Three-year follow-up of the Oxford Cholesterol Study (Assessment of the efficacy and safety of simvastatin in preparation for a large mortality study) . Eur Heart J . 1994;15:255–269
  21. Baigent C , Landray MJ . Study of Heart and Renal Protection (SHARP) . Kidney Int Suppl . 2003;84:S207–S210
  22. García Rodríguez LA , Hernández-Díaz S , de Abajo FJ . Association between aspirin and upper gastrointestinal complications (Systematic review of epidemiologic studies) . Br J Clin Pharmacol . 2001;52:563–571
  23. Kimberly RP , Plotz PH . Aspirin-induced depression of renal function . N Engl J Med . 1977;296:418–424
  24. Berg KJ . Acute effects of acetylsalicylic acid in patients with chronic renal insufficiency . Eur J Clin Pharmacol . 1977;11:111–116
  25. Minuz P , Barrow SE , Cockcroft JR , Ritter JM . Effects of non-steroidal anti-inflammatory drugs on prostacyclin and thromboxane synthesis in patients with essential hypertension . Br J Clin Pharmacol . 1990;30:519–526
  26. Rexrode KM , Buring JE , Glynn RJ , Stampfer MJ , Youngman LD , Gaziano JM . Analgesic use and renal function in men . JAMA . 2001;286:315–321
  27. Drey N , Roderick P , Mullee M , Rogerson M . A population-based study of the incidence and outcomes of diagnosed chronic kidney disease . Am J Kidney Dis . 2003;42:677–684

 The HARP pilot studies and the Study of Heart and Renal Protection (SHARP) were funded by unrestricted grants from Merck & Co. C.B., M.L., J.A., and R.C. each received reimbursement from Merck for travel expenses in connection with various speaking engagements, but as members of the Clinical Trial Service Unit, comply with the Unit’s policy of not accepting honoraria. See Appendix for UK-HARP Pilot Study Investigators.

 Originally published online as doi:10.1053/j.ajkd.2004.11.015 on January 25, 2005.

PII: S0272-6386(04)01596-3

doi: 10.1053/j.ajkd.2004.11.015

American Journal of Kidney Diseases
Volume 45, Issue 3 , Pages 473-484 , March 2005

Article Tools